Canada· CA-DIN-02409720
TUDORZA GENUAIR
A aclidinium bromide product containing aclidinium bromide, registered in Canada by COVIS PHARMA GMBH. The same ATC class is registered in 12 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Aclidinium bromide is registered in 12 of 19 countries.
Countries holding a registration under ATC R03BB05 (aclidinium bromide), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Aclidinium bromide · ATC R03BB05
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of aclidinium bromide costs, country by country.
Normalised to the WHO defined daily dose (0.644 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Aclidinium bromide · price per daily dose (0.644 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.32
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- ACLIDINIUM BROMIDE
- Manufacturer
- COVIS PHARMA GMBH
- Country
- Canada (CA)
- ATC code
- R03BB05
- ATC class
- Aclidinium bromide
- Defined daily dose
- 0.644 mg, Inhal
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
114 interactions on record for aclidinium bromide.
Graded by severity as the source publishes them — 113 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aclidinium bromide · interactions on record
114 records
- 113 moderate
- 1 minor
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aclidinium bromide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAclidinium bromide 375micrograms/dose dry powder inhalerJ M McGill Ltd
- CzechiaBRETARIS GENUAIRCovis Pharma Europe B.V., Amsterdam
- BelgiumBretaris Genuair 322 µgCovis Pharma Europe
- FinlandBretaris GenuairCOVIS PHARMA EUROPE B.V.
- IrelandBretaris Genuair 322 micrograms inhalation powderCovis Pharma Europe B.V.
- ItalyBRETARIS GENUAIR*polv inal 1 flacone 60 dosi 322 mcgCOVIS PHARMA EUROPE BV
- NetherlandsBretaris Genuair 322 microgram inhalatiepoederCovis Pharma Europe B.V.
- IcelandBretaris GenuairCovis Pharma Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bretaris Genuair, Eklira Genuair
- Liechtenstein · Bretaris Genuair, Eklira Genuair
- Norway · Bretaris Genuair, Eklira Genuair
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/95a41e43-9c10-43af-a457-68a359ce433c GET /v1/drugs/95a41e43-9c10-43af-a457-68a359ce433c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02409720",
"form": "POWDER (METERED DOSE)",
"class": "Human",
"routes": [
"INHALATION"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "R03BB05",
"schedule": [
"Prescription"
],
"drug_code": "89440",
"strengths": [
"400 MCG"
],
"ahfs_class": null,
"substances": [
"ACLIDINIUM BROMIDE"
],
"product_categorization": null
}See everything about aclidinium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.